Editorial: The promises of personalized medicine

European Journal of Clinical Pharmacology

Volumn 66, Issue 8, 2010, Pages 749-754

  Cascorbi, Ingolf ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Adverse drug events; Individualized medicine; Pharmacogenetics; Pharmacogenomics; Tailored medicine

Indexed keywords

ABACAVIR; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; ATOMOXETINE; ATORVASTATIN; AZATHIOPRINE; BUSULFAN; CARBAMAZEPINE; CELECOXIB; CETUXIMAB; CLOPIDOGREL; DASATINIB; ERLOTINIB; FLUOXETINE; GEFITINIB; IMATINIB; IRINOTECAN; ISONIAZID; LAPATINIB; MARAVIROC; NILOTINIB; PANITUMUMAB; PRASUGREL; PRIMAQUINE; RASBURICASE; RETINOIC ACID; TRASTUZUMAB; UNINDEXED DRUG; VORICONAZOLE; WARFARIN; DRUG;

ANTICOAGULATION; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DISEASE PREDISPOSITION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DYSLIPIDEMIA; EDITORIAL; EPILEPSY; EVIDENCE BASED MEDICINE; GENETIC ANALYSIS; GENETIC MARKER; HEALTH CARE; HEALTH CARE DELIVERY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY; INFECTION; INFLAMMATION; NEUROPATHIC PAIN; ONCOLOGY; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; THROMBOSIS; CLINICAL PHARMACOLOGY; DRUG THERAPY; GENOMICS; METABOLISM; METHODOLOGY; PERSONALIZED MEDICINE; STANDARD;

DRUG THERAPY; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PHARMACOLOGY, CLINICAL;

EID: 77955558435     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0858-6     Document Type: Editorial

References (31)

1. E Abrahams GS Ginsburg M Silver 2005 The Personalized Medicine Coalition: goals and strategies Am J Pharmacogenomics 5 345 355 10.2165/00129785- 200505060-00002 16336000 (Pubitemid 41783781)
2. Butler AW, Cohen-Woods S, Farmer A, McGuffin P, Lewis CM (2010) Integrating phenotypic data for depression. J Integr Bioinform 7. doi: 10.2390/biecoll-jib-2010-136
3. Y Caraco S Blotnick M Muszkat 2008 CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study Clin Pharmacol Ther 83 460 470 10.1038/sj.clpt. 6100316 1:CAS:528:DC%2BD1cXitlGnsbs%3D 17851566 (Pubitemid 351272635)
4. CD Collins S Purohit RH Podolsky HS Zhao D Schatz SE Eckenrode P Yang D Hopkins A Muir M Hoffman RA McIndoe M Rewers JX She 2006 The application of genomic and proteomic technologies in predictive, preventive and personalized medicine Vascul Pharmacol 45 258 267 10.1016/j.vph.2006.08.003 1:CAS:528:DC%2BD28Xht1CqtbbP 17030152 (Pubitemid 44765288)
5. G D'Andrea RL D'Ambrosio P Di Perna M Chetta R Santacroce V Brancaccio E Grandone M Margaglione 2005 A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin Blood 105 645 649 10.1182/blood-2004-06-2111 15358623 (Pubitemid 40070748)
6. M Eichelbaum M Ingelman-Sundberg WE Evans 2006 Pharmacogenomics and individualized drug therapy Annu Rev Med 57 119 137 10.1146/annurev.med.56. 082103.104724 1:CAS:528:DC%2BD28Xis1Cks70%3D 16409140 (Pubitemid 43261982)
7. N Fleeman R Dickson 2009 Providing patients with information on pharmacogenetic testing Nurs Stand 23 46 48 19248450
8. FW Frueh 2010 Real-world clinical effectiveness, regulatory transparency and payer coverage: three ingredients for translating pharmacogenomics into clinical practice Pharmacogenomics 11 657 660 10.2217/pgs.10.46 1:CAS:528:DC%2BC3cXlt1Cmt7s%3D 20415556
9. Gerr H, Zimmermann M, Schrappe M, Dworzak M, Ludwig WD, Bradtke J, Moericke A, Schabath R, Creutzig U, Reinhardt D (2010) Acute leukaemias of ambiguous lineage in children: characterization, prognosis and therapy recommendations. Br J Haematol 149:84-92
10. PM Ho TM Maddox L Wang SD Fihn RL Jesse ED Peterson JS Rumsfeld 2009 Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome JAMA 301 937 944 10.1001/jama.2009.261 1:CAS:528:DC%2BD1MXivFejt7g%3D 19258584
11. JM Hoskins RM Goldberg P Qu JG Ibrahim HL McLeod 2007 UGT1A128 genotype and irinotecan-induced neutropenia: dose matters J Natl Cancer Inst 99 1290 1295 10.1093/jnci/djm115 1:CAS:528:DC%2BD2sXhtVWqtbnI 17728214 (Pubitemid 47394168)
12. J Kirchheiner K Brosen ML Dahl LF Gram S Kasper I Roots F Sjoqvist E Spina J Brockmoller 2001 CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages Acta Psychiatr Scand 104 173 192 10.1034/j.1600-0447.2001.00299.x 1:CAS:528:DC%2BD3MXmvVekurg%3D 11531654 (Pubitemid 32762271)
13. J Kirchheiner U Fuhr J Brockmoller 2005 Pharmacogenetics-based therapeutic recommendations-ready for clinical practice? Nat Rev Drug Discov 4 639 647 10.1038/nrd1801 1:CAS:528:DC%2BD2MXmvVOqtrc%3D 16056390 (Pubitemid 41149757)
14. Kirchheiner J, Seeringer A, Viviani R (2010) Pharmacogenetics in psychiatry-a useful clinical tool or wishful thinking for the future? Curr Pharm Des 16:136-44
15. TE Klein RB Altman N Eriksson BF Gage SE Kimmel MT Lee NA Limdi D Page DM Roden MJ Wagner MD Caldwell JA Johnson 2009 Estimation of the warfarin dose with clinical and pharmacogenetic data N Engl J Med 360 753 764 10.1056/NEJMoa0809329 19228618
16. B Laika S Leucht S Heres W Steimer 2009 Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening? Pharmacogenomics J 9 395 403 10.1038/tpj.2009.23 1:CAS:528:DC%2BD1MXmtVOru7c%3D 19451914
17. S Mallal E Phillips G Carosi JM Molina C Workman J Tomazic E Jagel-Guedes S Rugina O Kozyrev JF Cid P Hay D Nolan S Hughes A Hughes S Ryan N Fitch D Thorborn A Benbow 2008 HLA-B5701 screening for hypersensitivity to abacavir N Engl J Med 358 568 579 10.1056/NEJMoa0706135 18256392 (Pubitemid 351214284)
18. JI Martin-Subero O Ammerpohl M Bibikova E Wickham-Garcia X Agirre S Alvarez M Bruggemann S Bug MJ Calasanz M Deckert M Dreyling MQ Du J Durig MJ Dyer JB Fan S Gesk ML Hansmann L Harder S Hartmann W Klapper R Kuppers M Montesinos-Rongen I Nagel C Pott J Richter J Roman-Gomez M Seifert H Stein J Suela L Trumper I Vater F Prosper C Haferlach CJ Cruz R Siebert 2009 A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms PLoS ONE 4 e6986 10.1371/journal.pone.0006986 19750229
19. JL Mega SL Close SD Wiviott L Shen RD Hockett JT Brandt JR Walker EM Antman W Macias E Braunwald MS Sabatine 2009 Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 354 362 10.1056/NEJMoa0809171 1:CAS:528:DC%2BD1MXhtVSlsbs%3D 19106084
20. JL Mega SL Close SD Wiviott L Shen RD Hockett JT Brandt JR Walker EM Antman WL Macias E Braunwald MS Sabatine 2009 Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes Circulation 119 2553 2560 10.1161/CIRCULATIONAHA.109.851949 1:CAS:528:DC%2BD1MXmtVKntrs%3D 19414633
21. B Mesko S Poliska A Szegedi Z Szekanecz K Palatka M Papp L Nagy 2010 Peripheral blood gene expression patterns discriminate among chronic inflammatory diseases and healthy controls and identify novel targets BMC Med Genomics 3 15 10.1186/1755-8794-3-15 20444268
22. A Moricke M Zimmermann A Reiter G Henze A Schrauder H Gadner WD Ludwig J Ritter J Harbott G Mann T Klingebiel F Zintl C Niemeyer B Kremens F Niggli D Niethammer K Welte M Stanulla E Odenwald H Riehm M Schrappe 2010 Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000 Leukemia 24 265 284 10.1038/leu.2009.257 1:STN:280:DC%2BC3c%2Fps1Wiuw%3D%3D 20010625
23. MC Muller NC Cross P Erben T Schenk B Hanfstein T Ernst R Hehlmann S Branford G Saglio A Hochhaus 2009 Harmonization of molecular monitoring of CML therapy in Europe Leukemia 23 1957 1963 10.1038/leu.2009.168 1:STN:280:DC%2BD1MjltFekuw%3D%3D 19710700
24. R Nanda 2007 Targeting the human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer: recent advances and future directions Rev Recent Clin Trials 2 111 116 10.2174/157488707780599375 1:CAS:528: DC%2BD2sXms1Oisr0%3D 18473995
25. M Pirmohamed 2006 Genetic factors in the predisposition to drug-induced hypersensitivity reactions AAPS J 8 E20 E26 10.1208/aapsj080103 1:CAS:528:DC%2BD28XjsVCisL8%3D 16584129 (Pubitemid 44603868)
26. NJ Samani P Deloukas J Erdmann C Hengstenberg K Kuulasmaa R McGinnis H Schunkert N Soranzo J Thompson L Tiret A Ziegler 2009 Large scale association analysis of novel genetic loci for coronary artery disease Arterioscler Thromb Vasc Biol 29 774 780 10.1161/ATVBAHA.108.181388 1:STN:280:DC%2BD1M3nvVKjsQ%3D%3D 19164808
27. E Schaeffeler C Fischer D Brockmeier D Wernet K Moerike M Eichelbaum UM Zanger M Schwab 2004 Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants Pharmacogenetics 14 407 417 10.1097/01.fpc.0000114745.08559.db 1:CAS:528:DC%2BD2cXlt1Cktrs%3D 15226673 (Pubitemid 38971231)
28. A Serretti A Chiesa R Calati G Perna L Bellodi D De Ronchi 2009 Common genetic, clinical, demographic and psychosocial predictors of response to pharmacotherapy in mood and anxiety disorders Int Clin Psychopharmacol 24 1 18 10.1097/YIC.0b013e32831db2d7 19060722
29. F Sjoqvist E Eliasson 2007 The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants Clin Pharmacol Ther 81 899 902 10.1038/sj.clpt.6100188 1:STN:280:DC%2BD2s3pt1ChsQ%3D%3D 17392719 (Pubitemid 46788300)
30. HY Yuan JJ Chen MT Lee JC Wung YF Chen MJ Charng MJ Lu CR Hung CY Wei CH Chen JY Wu YT Chen 2005 A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity Hum Mol Genet 14 1745 1751 10.1093/hmg/ddi180 1:CAS:528: DC%2BD2MXmvV2htL0%3D 15888487 (Pubitemid 41430097)
31. Zackrisson AL, Lindblom B, Ahlner J (2009) High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases. Clin Pharmacol Ther. doi: 10.1038/clpt.2009.216